Filtered By:
Management: Budgets

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 414 results found since Jan 2013.

New York City Garden 2016
It’s been a long year or so without our balcony herb garden. Mandatory brickwork outside our apartment started in April 2015 with a Cristo-like gauze wrapping around the entire facade and taping shut our windows and balcony door. We lived like that for almost an entire year, until finally, in April, we were allowed access to the balcony again. That’s the bad part. The good part is that I got to start the balcony garden all over again. The building had removed our handmade deck floor, so I replaced it with a wonderful and inexpensive Ikea deck floor. I also swapped out our rusting bistro set and rickety plant ...
Source: The Blog That Ate Manhattan - June 27, 2016 Category: Primary Care Authors: Margaret Polaneczky, MD Tags: Gardening Balcony garden Best garden supplies NYC Garden centers NYC Manhattan New York New York City resources Urban gardening Source Type: blogs

Government Appropriation Of Breakthrough Drug Patent Rights Would Deter Biopharmaceutical R&D And Innovation
In the May 2016 issue of Health Affairs, Amy Kapezynski and Aaron Kesselheim propose that the federal government invoke its patent use authority under Section 1498 to lower drug prices and increase access for breakthrough medicines in government-funded health care programs. Section 1498 allows the government eminent domain-type powers to circumvent an inventor’s patent exclusivity rights in exchange for “reasonable and entire compensation” — in effect a royalty on sales which would be determined through negotiation or by the courts. To date, application of Section 1498 has been limited to selective military and...
Source: Health Affairs Blog - June 20, 2016 Category: Health Management Authors: Henry Grabowski Tags: Costs and Spending Drugs and Medical Technology Big Pharma Cooperative Research and Development Agreements eminent domain hepatitis C Section 1498 Sovaldi Source Type: blogs

This doctor was remembered for his devotion to patients. Was it enough?
Recently I attended the funeral of a prominent gastroenterologist in my community whom I knew socially as the father of my son’s friend. It was an untimely and rapid death due to pancreatic cancer. He left behind a young wife and four children, two of whom are in college. I would see him periodically at school functions; he would sneak into an event at the last minute and often struggle to stay awake through squeaky orchestra concerts or long school administration speeches on the district’s budget goals. Very often he would rush out right as the event ended to go back to the office and finish up his chart work. He had ...
Source: Kevin, M.D. - Medical Weblog - June 12, 2016 Category: Journals (General) Authors: Tags: Physician Primary care Source Type: blogs

America’s New Drug War
By STEVEN FINDLAY Earlier this month an 86-year old man in Florida killed his 78-year old wife.  He called 911 and when the cops arrived he confessed.  When asked why he did it, the man told authorities that the couple could no longer afford her medications.  She’d been sick for 15 years, the man said, and was often in pain.  News sources reported that the couple filed for bankruptcy in 2011.  At the time, they had $53,900 in liabilities, most in medical bills put on their credit card.   They lived primarily on social security.     There’s very likely more to this sad story, and it’s unclear why Medicare did...
Source: The Health Care Blog - May 29, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs

Fight Aging! Newsletter, May 30th 2016
This study expands on the idea that loss of Y, already a known risk factor for cancer, could be a predictive biomarker for a wider range of poor health outcomes, specifically Alzheimer's. Why loss of Y can be linked to an increased risk for disease remains unclear, but the authors speculate it has to do with reduced immune system performance. The researchers looked at over 3,000 men to ascertain whether there was any predictive association between loss of Y in blood cells and Alzheimer's disease. The participants came from three long-term studies that could provide regular blood samples: the European Alzheimer's Dis...
Source: Fight Aging! - May 29, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Preventing A Thousand Flints: Getting Reform Of Chemical Regulation Right
The contamination of water with lead in Flint, Michigan has rightly refocused national attention on the ongoing tragedy of childhood lead exposure in the United States. As John Oliver has rightly and wittily noted, water is but one source of exposure; another compelling tragedy is our ongoing failure to fund the control of lead-based paint hazards, which represent a large and preventable source of childhood lead exposure. Prevention of childhood lead exposure makes good economic sense: for every $1 invested in protecting children from lead hazards in their home, society would benefit between $17 and $220. This cost-benefit...
Source: Health Affairs Blog - May 23, 2016 Category: Health Management Authors: Leonardo Trasande and Bruce Lanphear Tags: Drugs and Medical Technology Featured Public Health Quality Environmental Health EPA Flint Lead poisoning Michigan Toxic Substances Control Act Source Type: blogs

Fight Aging! Newsletter, May 16th 2016
In this study the authors demonstrate that, as in many other cases, the methodology of delivery matters just as much as the details of the cells used: Retinal and macular degenerative diseases affect millions of people worldwide. Similar to other neurodegenerative diseases, there are no effective treatments that can stop retinal degeneration or restore degenerative retina. Recent advances in stem cell technology led to development of novel cell-based therapies, some are already in phase I/II clinical trials. Studies from our group and others suggest that human bone marrow-derived mesenchymal stem cells (hBM-MSC) m...
Source: Fight Aging! - May 15, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Would A Wider Variety Of Vial Sizes Reduce The Cost Of Chemotherapy? Not Likely
The high prices of many patented pharmaceuticals, especially chemotherapy drugs, pose substantial challenges to the budgets of public programs, private insurers, and patients and their families. Addressing this problem in the US context, through changes in drug negotiating rules, reimportation, price controls, or patent reform is pragmatically daunting and politically fraught. It’s natural, then, to seek ways around the problem — options that might reduce the price of drugs while sidestepping that charged territory. Vial Size In a March 1, 2016 article published in BMJ, Peter Bach and colleagues propose one such st...
Source: Health Affairs Blog - May 11, 2016 Category: Health Management Authors: Sherry Glied and Bhaven Sampat Tags: Costs and Spending Drugs and Medical Technology Featured Health Professionals Hospitals Quality Big Pharma chemotherapy vial sizes Source Type: blogs

Negligibly Senescent Species in the Context of Longevity Science
This popular science article focuses on the study of negligibly senescent species in the context of work aimed at adjusting the course of human aging. There is at least one negligibly senescent mammal, the naked mole-rat, but it seems to me that attempting to mine benefits from other species and port them to humans is just another way to say we should re-engineer human metabolism to age more slowly. The past twenty years have demonstrated that this is enormously expensive and enormously challenging. Billions have been spent on trying to safely change just a few genes and proteins, and to try to better understand the modest...
Source: Fight Aging! - May 11, 2016 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

It is Vital to Accelerate Development of Means to Effectively Treat the Causes of Aging
In the long sweep of human history, there has never been an age in which advocacy could have made as big a difference as advocacy for aging research can make today. The scientific community stands at the gates of rejuvenation, of the effective medical control over the causes of aging. The forms of cell and tissue damage that distinguish old tissues from young tissues are cataloged. The consensus position in the research community is that accumulation of this damage causes aging. Rejuvenation therapies capable of repairing, preventing, or working around the damage of aging are not in the clinic yet, but are at various stage...
Source: Fight Aging! - May 9, 2016 Category: Research Authors: Reason Tags: Activism, Advocacy and Education Source Type: blogs

My Greatest Professional Accomplishment Was a Bureaucratic Miracle
When we achieve our all-time greatest professional accomplishment, we know it right away. Like Dr. Carl June developing a novel way to treat cancer, Mark Sanchez not throwing an interception, and me breaking through bureaucracy in the U.S. federal government to author a column in my organization's 18,000-circulation newsletter.Last summer, the communications office where I work wanted to create a new feature in our newsletter focusing on a different employee every other week. They asked me to write it. They said, "We want it to be about people's day-to-day lives at work."I said, "That's boring, how about instead I intervie...
Source: cancerslayerblog - May 9, 2016 Category: Cancer & Oncology Tags: writing/speaking Source Type: blogs

Tweet Your Support for Cancer Survivors to Members of Congress
LIVESTRONG supporters are in Washington, D.C., for the One Voice Against Cancer (OVAC) annual lobby day urging Congress to make cancer a top national priority, and you can help advance their message. The LIVESTRONG Foundation is a member of OVAC, a coalition of 49 nonprofit organizations that believe robust federal funding is crucial to making advances in cancer prevention, treatment and research. While on Capitol Hill, advocates will ask that federal agencies working to fight cancer receive increased funding. WE NEED YOU to help amplify our message by sending one of the suggested messages below to YOUR members of Congress...
Source: LIVESTRONG Blog - May 8, 2016 Category: Cancer & Oncology Authors: Cameron Krier Massey (LIVESTRONG Staff) Source Type: blogs

A Controversial New Demonstration In Medicare: Potential Implications For Physician-Administered Drugs
According to an August 2015 survey, 72 percent of Americans find drug costs unreasonable, with 83 percent believing that the federal government should be able to negotiate prices for Medicare. Recently, Acting Administrator of the Centers for Medicare and Medicaid Services (CMS) Andy Slavitt commented that spending on medicines increased 13 percent in 2014 while health care spending growth overall was only 5 percent, the highest rate of drug spending growth since 2001. Some of the most expensive drugs are covered under Medicare’s medical benefit, Part B, because they are administered by a physician. They are often admini...
Source: Health Affairs Blog - May 3, 2016 Category: Health Management Authors: Kavita Patel and Caitlin Brandt Tags: Costs and Spending Featured Medicare Payment Policy Quality Avastin CMMI Lucentis Medicare Part B oncology care model prescription drug coverage Source Type: blogs

Value Pricing For Drugs: Whose Value, What Price?
It is hard to read a newspaper these days without coming across a story about the high and ever increasing cost of drugs. The Wall Street Journal named drug prices the top health story of 2015. Stories about drug prices fall into two general categories. The first are stories about generic and other manufacturers who are not focused on innovation (like Turing Pharmaceuticals and Valeant) but who acquire generic drugs and increase the price dramatically without adding value while also making it impossible for competitors to manufacture the drug by controlling the distribution. While this problem is real, it is not the focus ...
Source: Health Affairs Blog - March 28, 2016 Category: Health Management Authors: Robert Rubin Tags: Costs and Spending Drugs and Medical Technology Featured Medicare ACOs Big Pharma cost effectiveness analysis high-cost drugs PCSK9 inhibitors QUALY value-based payment Source Type: blogs

The Economics Of Paying For Value
Editor’s note: This post is part of a Health Affairs Blog Symposium on Health Law stemming from 4th Annual Health Law Year in P/Review conference hosted by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Holly Fernandez Lynch wrote an introductory post in January 2016 and you can access a full list of symposium pieces here or by clicking on the “The Health Law Year in P/Review” tag at the bottom of any symposium post. You can also watch a video of the presentation on which this post is based. The notion that the American health care system should transition from ...
Source: Health Affairs Blog - March 15, 2016 Category: Health Management Authors: Nancy Beaulieu, Michael Chernew, Soren Kristensen and Meredith Rosenthal Tags: Costs and Spending Featured Payment Policy Population Health Quality ACOs fee-for-service The Health Law Year in P/Review value-based payment Source Type: blogs